Cardiovascular Drugs and Therapy

, Volume 20, Issue 1, pp 5–8 | Cite as

Synergistic Effects of Atorvastatin and Sildenafil in Cardioprotection—Role of NO



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Edwards P, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Ann Rev Biochem 1999;68:157–185.CrossRefPubMedGoogle Scholar
  2. 2.
    Lefer AM, Campbell B, Shin Y, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic–reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999;100:178–184.PubMedGoogle Scholar
  3. 3.
    Scalia R, Gooszen SP, Jones M, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001; 103:2598–2603.PubMedGoogle Scholar
  4. 4.
    Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Inv. 1998;101:2711–2719.Google Scholar
  5. 5.
    Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129–1135.PubMedGoogle Scholar
  6. 6.
    Kureishi Y, Shiojima I, Bialik A, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;9:1004–1010.Google Scholar
  7. 7.
    Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508–515.CrossRefPubMedGoogle Scholar
  8. 8.
    Chou E, Salloum F, Ockaili R, Bremer Y, Kukreja RC. Atorvastatin triggers early and delayed myocardial protection in-vivo: role of nitric oxide and mitochondrial KATP channels Circulation 2003;102:(Suppl)II–157 (Abstract).Google Scholar
  9. 9.
    Chen JC, Huang KC, Lin WW. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways. Cell Signal 2006;18:32–39.CrossRefPubMedGoogle Scholar
  10. 10.
    Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868–873.CrossRefPubMedGoogle Scholar
  11. 11.
    Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933–1939.CrossRefPubMedGoogle Scholar
  12. 12.
    Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104:982–985.PubMedGoogle Scholar
  13. 13.
    Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124–1129.CrossRefPubMedGoogle Scholar
  14. 14.
    Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691–696.CrossRefPubMedGoogle Scholar
  15. 15.
    Pan W, Pintar T, Anton J, Lee V-V, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004(11 Suppl 1); 110:II45–II49.PubMedGoogle Scholar
  16. 16.
    Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47–52.PubMedGoogle Scholar
  17. 17.
    Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192–199.CrossRefPubMedGoogle Scholar
  18. 18.
    Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999;36:275–328.CrossRefPubMedGoogle Scholar
  19. 19.
    Senzaki H, Juang GJ, Isoda T, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. Faseb J 2001;15:1718–1726.CrossRefPubMedGoogle Scholar
  20. 20.
    Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor, sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of NO signaling. J Biol Chem 2005;280:12944–12955.CrossRefPubMedGoogle Scholar
  21. 21.
    Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282–290.CrossRefGoogle Scholar
  22. 22.
    Eardley I, Cartledge J. Tadalafil (Cialis) for men with erectile dysfunction. Int J Clin Pract 2002;56:300–304.PubMedGoogle Scholar
  23. 23.
    Kukreja RC, Salloum F, Das A, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 2005;42:219–232.CrossRefPubMedGoogle Scholar
  24. 24.
    Kukreja RC, Ockaili R, Salloum F, et al. Cardioprotection with phosphodiesterase-5 inhibition—a novel preconditioning strategy. J Mol Cell Cardiol 2004;36:165–173.CrossRefPubMedGoogle Scholar
  25. 25.
    Ockaili R, Salloum F, Hawkin J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol 2002;283:H1263–H1269.Google Scholar
  26. 26.
    Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 2005;57:22–27.CrossRefPubMedGoogle Scholar
  27. 27.
    Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003;92:595–597.CrossRefPubMedGoogle Scholar
  28. 28.
    Salloum F, Xi L, Ockaili R, Yin C, Kukreja RC. Delayed pharmacological preconditioning with Viagra (Sildenafil) against myocardial infarction is independent of p38 MAPK signaling pathway. Circulation 2002;102(Suppl):II–378.Google Scholar
  29. 29.
    Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005;111:1601–1610.CrossRefPubMedGoogle Scholar
  30. 30.
    Nagy O, Hajnal A, Parratt JR, Agnes V. Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 2004;141:549–551.CrossRefPubMedGoogle Scholar
  31. 31.
    Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214–222.CrossRefPubMedGoogle Scholar
  32. 32.
    Das A, Ockaili R, Salloum F, Kukreja RC. Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol 2004;286:455–460.Google Scholar
  33. 33.
    Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang M-H, Uretsky BF, Birnbaum Y. Enhanced cardioprotection against Ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drug Therap 2006 In press.Google Scholar
  34. 34.
    Vinten-Johansen J, Zhao ZQ, Corvera JS, et al. Adenosine in myocardial protection in on-pump and off-pump cardiac surgery. Ann Thorac Surg 2003;75:S691–S699.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Internal MedicineVirginia Commonwealth UniversityRichmondUSA
  2. 2.Division of CardiologyVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations